Helen Louise Collins, Enliven Therapeutics' chief medical officer, executed a sale of 4,900 shares of the company's common stock on April 17, 2026, producing proceeds of approximately $238,352. The shares were sold at prices between $45.8107 and $48.0555 per share, levels that sit close to Enliven's 52-week high of $48.53.
The sale was carried out pursuant to a Rule 10b5-1 trading plan that Collins established on October 19, 2025. Rule 10b5-1 plans allow insiders to set prearranged transactions, and the company disclosed that the April 17 sales were part of that arrangement.
Immediately prior to the sale, Collins exercised 5,000 stock options in Enliven Therapeutics at an exercise price of $2.48 per share, for a total cash outlay of $12,400. Those options were reported as fully vested and exercisable at the time of exercise.
After accounting for the exercise and the subsequent sale, Collins' direct holdings in Enliven's common stock stand at 25,000 shares. Some portion of these shares are held as Restricted Stock Units, each representing a contingent right to receive one share of common stock. In addition to direct holdings, Collins continues to hold 131,268 derivative securities in the form of stock options.
Enliven's share price movement has been pronounced year-to-date, with the company delivering a 198% return during that period. The firm currently trades with a market capitalization of $2.73 billion. At the same time, third-party analysis from InvestingPro noted in disclosures that the stock may be overvalued at current levels.
Analysts maintain a broadly favorable view on Enliven's shares. Consensus coverage reflects a strong buy stance, with price targets spanning from $41 to $60. In recent analyst activity tied to developments in the oncology sector, H.C. Wainwright raised its price target on Enliven to $56 from $48 while keeping a Buy rating. Clear Street reiterated its Buy rating and assigned a $36 price target, citing the potential of Enliven's chronic myeloid leukemia therapy in the context of an important deal in the sector.
The analyst attention followed the announcement that Merck reached a definitive agreement to acquire Terns Pharmaceuticals for $53 per share in cash, valuing that transaction at roughly $6.7 billion. The Terns acquisition has been highlighted by market participants as underscoring the sizeable opportunity for safer and more effective chronic myeloid leukemia therapies. Published estimates cited in coverage indicate the U.S. market for such therapies is expected to exceed $9 billion.
That acquisition process has also generated transactional detail that drew scrutiny across the sector. Reports note the deal is anticipated to close next quarter and that Merck's acquisition proposal initially matched that of an unnamed party, with both proposals offering $61 per share in cash for Terns at one point during the process. Observers cited these developments as reflective of strong strategic interest and competition in oncology assets.
The insider sale by Enliven's CMO, combined with a recent option exercise and a sizable holding in derivatives, presents a clear snapshot of executive-level positioning in the company amid elevated share prices and renewed analyst focus. The juxtaposition of sizable year-to-date gains, bullish analyst targets, and third-party caution about valuation leaves market participants with multiple factors to weigh as the sector continues to evolve.
Summary of transactions and holdings
- 4,900 shares sold on April 17, 2026 - proceeds approx. $238,352 - sale prices $45.8107 to $48.0555.
- Rule 10b5-1 trading plan adopted October 19, 2025 used to execute the sale.
- Prior exercise of 5,000 options at $2.48 per share for $12,400; options fully vested.
- Post-transaction direct holdings: 25,000 common shares; 131,268 stock options outstanding.